Altria (MO) Sues FDA Over Product Review Delays, Targets Faster Approvals for On! Nicotine Pouches

Altria Group (NYSE: MO) filed a lawsuit against the U.S. Food and Drug Administration this week, asserting that the agency’s tobacco product review system has routinely failed to meet the statutory 180-day decision deadline required by law. The company specifically pointed to extended delays in its On! nicotine pouch applications, arguing the agency’s backlog has unfairly allowed unregulated foreign competitors to gain market share.

The lawsuit was filed in a federal court in Lubbock, Texas, and seeks to compel the FDA to overhaul its Pre-market Tobacco Product Application (PMTA) review process to ensure timely decisions. Altria claims the FDA’s failure to adhere to legally mandated timelines has suppressed the rollout of newer nicotine products, such as its On! line, while enforcement against unauthorized products remains lax, further hurting compliant manufacturers.

This legal action—a material development within the past week—targets the regulatory environment critical for Altria’s smoke-free product strategy, particularly its On! nicotine pouches. It underscores the company’s frustration with the pace of regulatory approvals, which it says is undermining both its competitive positioning and strategic consumer harm-reduction efforts.

From an investor standpoint, the lawsuit introduces regulatory risk but also stands as a proactive attempt to clear a path for In-market expansion of Altria’s smoke-free offerings. Successfully accelerating FDA review timelines could be a catalyst for growth in On! and related product lines.

Meanwhile, shares of Altria (MO) traded at $68.88 as of September 24, 2026, reflecting a daily decline of 0.89%. While it remains unclear whether this movement relates directly to the lawsuit, the filing may heighten investor attention on regulatory outcomes for the company’s smoke-free segment.

Looking ahead, investors should monitor developments in this litigation, including court responses and any FDA commentary, as outcomes could materially influence Altria’s product launch timeline and longer-term growth in the nicotine pouch market.